Evidence map›Paper›PMID 39104432›Full record

ArticleThe mental health clinician2024

Exploring the harm reduction paradigm: the role of Board-Certified Psychiatric Pharmacists.

Amber R Douglass, Ashley Maister, Karen E Moeller, Aaron Salwan, Anuja Vallabh, Kristin Waters, Gregory H Payne

Registry-linked trialAbstract read
In one paragraph

Article in The mental health clinician, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07211724 (Methamphetamine Use Disorder Support in Heart Failure), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07211724 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Methamphetamine Use Disorder Support in Heart Failure (Meth HF) Pilot Study

TypeinterventionalSponsorUniversity of Southern CaliforniaRan2026 to 2027Enrolled50ConditionsHeart Failure, Methamphetamine Use DisorderArmsMUD Management (contingency management +/- adjunctive MUD pharmacotherapy), HF GDMT management
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amber R DouglassClinical Pharmacist Practitioner - Mental Health, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.ORCID https://orcid.org/0000-0001-5960-1941
Ashley MaisterClinical Pharmacist Practitioner - Mental Health, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.ORCID https://orcid.org/0000-0002-7875-3403
Karen E MoellerClinical Professor, University of Kansas, Kansas City, Kansas.ORCID https://orcid.org/0000-0002-2863-8335
Aaron SalwanClinical Pharmacy Specialist, Behavioral Health, Montefiore Nyack Hospital, Nyack, New York.ORCID https://orcid.org/0000-0002-2963-0589
Anuja VallabhSUD/MH Clinical Pharmacist Practitioner, VISN 12 Clinical Resource Hub - Jesse Brown VA Medical Center, Chicago, Illinois.ORCID https://orcid.org/0000-0002-5878-5862
Kristin WatersAssistant Clinical Professor, University of Connecticut, Storrs, Connecticut.ORCID https://orcid.org/0000-0002-2278-1018
Gregory H PayneDirector of Strategic Initiatives, American Association of Psychiatric Pharmacists, Lincoln, Nebraska.ORCID https://orcid.org/0000-0002-8592-7280

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deaths related to opioid overdoses continue to climb, and there remains a need for innovative strategies to address this ongoing crisis. Harm reduction (HR), a nonjudgmental philosophy aimed at reducing consequences associated with drug use and other potentially unsafe behavior, has emerged as a compassionate and effective approach. Harm reduction further emphasizes overdose prevention and fosters a shift in perspective that recognizes substance use disorder as a disease and not a moral failing. The tenets of HR collectively advocate for the well-being of individuals who use substances and support any positive change as defined by the individual. Given the high rate of morbidity and mortality associated with substance misuse and barriers or ambivalence to receiving treatment, awareness of and advocacy for HR practice is essential. This manuscript aims to describe evidence-based HR interventions, provide a foundation for the implementation of services, and further promote the importance of providing humanistic care without judgment. As valued members of the multidisciplinary treatment team, Board-Certified Psychiatric Pharmacists should implement and engage in HR services in the settings where people with substance use disorders receive care.

Indexed as

harm reductionpsychiatric pharmacistssubstance use disorders

Identifiers

PMID39104432
PMCPMC11298032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.